Combination of trastuzumab and pertuzumab with FOLFOXIRI as the neoadjuvant therapeutic tegimen for HER2-positive resectable metastatic colorectal cancer: The first case report

類似資料

• Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer
  著者:: Xueying Wu, 等
  出版事項: (2022-01-01)
• Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
  著者:: Page E. Blas, 等
  出版事項: (2024-03-01)
• Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
  著者:: Abdullah Evren YETİŞİR, 等
  出版事項: (2021-08-01)
• Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis
  著者:: Francisco Cezar Aquino de Moraes, 等
  出版事項: (2025-03-01)
• Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
  著者:: Gavin P. Dowling, 等
  出版事項: (2024-01-01)